November 10, 2023
Daiichi Sankyo said on November 9 that it has obtained European regulatory approval for its FLT3 inhibitor Vanflyta (quizartinib) for the first-line treatment of patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML). The approval was awarded for the drug’s...read more